Search

Your search keyword '"Ballweber-Fleming, Lamar"' showing total 14 results
Start Over Author "Ballweber-Fleming, Lamar"
14 results on '"Ballweber-Fleming, Lamar"'

2. Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming

Author

deCamp, Allan C., Corcoran, Martin M., Fulp, William J., Willis, Jordan R., Cottrell, Christopher A., Bader, Daniel L. V., Kalyuzhniy, Oleksandr, Leggat, David J., Cohen, Kristen W., Hyrien, Ollivier, Menis, Sergey, Finak, Greg, Ballweber-Fleming, Lamar, Srikanth, Abhinaya, Plyler, Jason R., Rahaman, Farhad, Lombardo, Angela, Philiponis, Vincent, Whaley, Rachael E., Seese, Aaron, Brand, Joshua, Ruppel, Alexis M., Hoyland, Wesley, Mahoney, Celia R., Cagigi, Alberto, Taylor, Alison, Brown, David M., Ambrozak, David R., Sincomb, Troy, Mullen, Tina-Marie, Maenza, Janine, Kolokythas, Orpheus, Khati, Nadia, Bethony, Jeffrey, Roederer, Mario, Diemert, David, Koup, Richard A., Laufer, Dagna S., McElrath, Juliana M., McDermott, Adrian B., Karlsson Hedestam, Gunilla B., and Schief, William R.

Published
2024
Full Text
View/download PDF

3. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies

Author

Hahn, William O., primary, Parks, K. Rachael, additional, Shen, Mingchao, additional, Ozorowski, Gabriel, additional, Janes, Holly, additional, Ballweber-Fleming, Lamar, additional, Woodward-Davis, Amanda, additional, Duplessis, Chris, additional, Tomei, Mark, additional, Dey, Antu K., additional, Sagawa, Zachary K., additional, De Rosa, Stephen C., additional, Seese, Aaron, additional, Siddaramaiah, Latha Kallur, additional, Stamatatos, Leonidas, additional, Lee, Wen-Hsin, additional, Sewall, Leigh M., additional, Karlinsey, Dalton, additional, Turner, Hannah L., additional, Rubin, Vanessa, additional, Furth, Sarah, additional, MacPhee, Kellie, additional, Duff, Michael, additional, Corey, Lawrence, additional, Keefer, Michael C., additional, Edupuganti, Srilattha, additional, Frank, Ian, additional, Maenza, Janine, additional, Baden, Lindsey R., additional, Hyrien, Ollivier, additional, Sanders, Rogier W., additional, Moore, John P., additional, Ward, Andrew B., additional, Tomaras, Georgia D., additional, Montefiori, David C., additional, Rouphael, Nadine, additional, and McElrath, M. Juliana, additional

Published
2024
Full Text
View/download PDF

4. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses

Author

Cohen, Kristen W., primary, De Rosa, Stephen C., additional, Fulp, William J., additional, deCamp, Allan C., additional, Fiore-Gartland, Andrew, additional, Mahoney, Celia R., additional, Furth, Sarah, additional, Donahue, Josh, additional, Whaley, Rachael E., additional, Ballweber-Fleming, Lamar, additional, Seese, Aaron, additional, Schwedhelm, Katharine, additional, Geraghty, Daniel, additional, Finak, Greg, additional, Menis, Sergey, additional, Leggat, David J., additional, Rahaman, Farhad, additional, Lombardo, Angela, additional, Borate, Bhavesh R., additional, Philiponis, Vincent, additional, Maenza, Janine, additional, Diemert, David, additional, Kolokythas, Orpheus, additional, Khati, Nadia, additional, Bethony, Jeffrey, additional, Hyrien, Ollivier, additional, Laufer, Dagna S., additional, Koup, Richard A., additional, McDermott, Adrian B., additional, Schief, William R., additional, and McElrath, M. Juliana, additional

Published
2023
Full Text
View/download PDF

5. Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming

Author

deCamp, Allan, primary, Corcoran, Martin, additional, Fulp, William, additional, Willis, Jordan, additional, Cottrell, Christopher, additional, Bader, Daniel, additional, Kalyuzhniy, Oleksandr, additional, Leggat, David, additional, Cohen, Kristen, additional, Hyrien, Ollivier, additional, Menis, Sergey, additional, Finak, Greg, additional, Ballweber Fleming, Lamar, additional, Srikanth, Abhinaya, additional, Plyler, Jason, additional, Rahaman, Farhad, additional, Lombardo, Angela, additional, Philiponis, Vincent, additional, Whaley, Rachael, additional, Seese, Aaron, additional, Brand, Joshua, additional, Ruppel, Alexis, additional, Hoyland, Wesley, additional, Mahoney, Celia, additional, Cagigi, Alberto, additional, Taylor, Alison, additional, Brown, David, additional, Ambrozak, David, additional, Sincomb, Troy, additional, MULLEN, Tina-Marie, additional, Maenza, Janine, additional, Kolokythas, Orpheus, additional, Khati, Nadia, additional, Bethony, Jeffrey, additional, Roederer, Mario, additional, Diemert, David, additional, Koup, Richard, additional, Laufer, Dagna, additional, McElrath, M., additional, McDermott, Adrian, additional, Karlsson Hedestam, Gunilla, additional, and Schief, William, additional

Published
2023
Full Text
View/download PDF

6. Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming

Author

deCamp, Allan C., Corcoran, Martin M., Fulp, William J., Willis, Jordan R., Cottrell, Christopher A., Bader, Daniel L.V., Kalyuzhniy, Oleksandr, Leggat, David J., Cohen, Kristen W., Hyrien, Ollivier, Menis, Sergey, Finak, Greg, Ballweber-Fleming, Lamar, Srikanth, Abhinaya, Plyler, Jason R., Rahaman, Farhad, Lombardo, Angela, Philiponis, Vincent, Whaley, Rachael E., Seese, Aaron, Brand, Joshua, Ruppel, Alexis M., Hoyland, Wesley, Mahoney, Celia R., Cagigi, Alberto, Taylor, Alison, Brown, David M., Ambrozak, David R., Sincomb, Troy, Mullen, Tina-Marie, Maenza, Janine, Kolokythas, Orpheus, Khati, Nadia, Bethony, Jeffrey, Roederer, Mario, Diemert, David, Koup, Richard A., Laufer, Dagna S., McElrath, Juliana M., McDermott, Adrian B., Hedestam, Gunilla B. Karlsson, and Schief, William R.

Subjects
Article
Abstract

Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8 60mer germline-targeting immunogen, higher frequencies of vaccine-induced VRC01-class bnAb-precursor B cells were observed in the high dose compared to the low dose group. Through immunoglobulin heavy chain variable (IGHV) genotyping, statistical modeling, quantification of IGHV1-2 allele usage and B cell frequencies in the naive repertoire for each trial participant, and antibody affinity analyses, we found that the difference between dose groups in VRC01-class response frequency was best explained by IGHV1-2 genotype rather than dose and was most likely due to differences in IGHV1-2 B cell frequencies for different genotypes. The results demonstrate the need to define population-level immunoglobulin allelic variations when designing germline-targeting immunogens and evaluating them in clinical trials.One-Sentence SummaryHuman genetic variation can modulate the strength of vaccine-induced broadly neutralizing antibody precursor B cell responses.

Published
2023

7. Vaccination induces HIV broadly neutralizing antibody precursors in humans

Author

Leggat, David J., primary, Cohen, Kristen W., additional, Willis, Jordan R., additional, Fulp, William J., additional, deCamp, Allan C., additional, Kalyuzhniy, Oleksandr, additional, Cottrell, Christopher A., additional, Menis, Sergey, additional, Finak, Greg, additional, Ballweber-Fleming, Lamar, additional, Srikanth, Abhinaya, additional, Plyler, Jason R., additional, Schiffner, Torben, additional, Liguori, Alessia, additional, Rahaman, Farhad, additional, Lombardo, Angela, additional, Philiponis, Vincent, additional, Whaley, Rachael E., additional, Seese, Aaron, additional, Brand, Joshua, additional, Ruppel, Alexis M., additional, Hoyland, Wesley, additional, Yates, Nicole L., additional, Williams, LaTonya D., additional, Greene, Kelli, additional, Gao, Hongmei, additional, Mahoney, Celia R., additional, Corcoran, Martin M., additional, Cagigi, Alberto, additional, Taylor, Alison, additional, Brown, David M., additional, Ambrozak, David R., additional, Sincomb, Troy, additional, Hu, Xiaozhen, additional, Tingle, Ryan, additional, Georgeson, Erik, additional, Eskandarzadeh, Saman, additional, Alavi, Nushin, additional, Lu, Danny, additional, Mullen, Tina-Marie, additional, Kubitz, Michael, additional, Groschel, Bettina, additional, Maenza, Janine, additional, Kolokythas, Orpheus, additional, Khati, Nadia, additional, Bethony, Jeffrey, additional, Crotty, Shane, additional, Roederer, Mario, additional, Karlsson Hedestam, Gunilla B., additional, Tomaras, Georgia D., additional, Montefiori, David, additional, Diemert, David, additional, Koup, Richard A., additional, Laufer, Dagna S., additional, McElrath, M. Juliana, additional, McDermott, Adrian B., additional, and Schief, William R., additional

Published
2022
Full Text
View/download PDF

8. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

Author

Gray, Matthew D., primary, Feng, Junli, additional, Weidle, Connor E., additional, Cohen, Kristen W., additional, Ballweber-Fleming, Lamar, additional, MacCamy, Anna J., additional, Huynh, Crystal N., additional, Trichka, Josephine J., additional, Montefiori, David, additional, Ferrari, Guido, additional, Pancera, Marie, additional, McElrath, M. Juliana, additional, and Stamatatos, Leonidas, additional

Published
2022
Full Text
View/download PDF

10. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain

Author

Gray, Matthew D., primary, Feng, Junli, additional, Weidle, Connor E., additional, Cohen, Kristen W., additional, Ballweber-Fleming, Lamar, additional, MacCamy, Anna J., additional, Huynh, Crystal N., additional, Trichka, Josephine J., additional, Montefiori, David, additional, Ferrari, Guido, additional, Pancera, Marie, additional, McElrath, M. Juliana, additional, and Stamatatos, Leonidas, additional

Published
2021
Full Text
View/download PDF

11. Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

Author

Andersen-Nissen, Erica, primary, Fiore-Gartland, Andrew, additional, Ballweber Fleming, Lamar, additional, Carpp, Lindsay N., additional, Naidoo, Anneta F., additional, Harper, Michael S., additional, Voillet, Valentin, additional, Grunenberg, Nicole, additional, Laher, Fatima, additional, Innes, Craig, additional, Bekker, Linda-Gail, additional, Kublin, James G., additional, Huang, Ying, additional, Ferrari, Guido, additional, Tomaras, Georgia D., additional, Gray, Glenda, additional, Gilbert, Peter B., additional, and McElrath, M. Juliana, additional

Published
2021
Full Text
View/download PDF

12. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection

Author

Astronomo, Rena D., primary, Santra, Sampa, additional, Ballweber-Fleming, Lamar, additional, Westerberg, Katharine G., additional, Mach, Linh, additional, Hensley-McBain, Tiffany, additional, Sutherland, Laura, additional, Mildenberg, Benjamin, additional, Morton, Georgeanna, additional, Yates, Nicole L., additional, Mize, Gregory J., additional, Pollara, Justin, additional, Hladik, Florian, additional, Ochsenbauer, Christina, additional, Denny, Thomas N., additional, Warrier, Ranjit, additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayapan, Sorachai, additional, Kaewkungwal, Jaranit, additional, Ferrari, Guido, additional, Shaw, George M., additional, Xia, Shi-Mao, additional, Liao, Hua-Xin, additional, Montefiori, David C., additional, Tomaras, Georgia D., additional, Haynes, Barton F., additional, and McElrath, M. Juliana, additional

Published
2016
Full Text
View/download PDF

13. HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies.

Author

Hahn WO, Parks KR, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Woodward Davis AS, Duplessis C, Tomai M, Dey AK, Sagawa ZK, De Rosa SC, Seese A, Siddaramaiah LK, Stamatatos L, Lee WH, Sewall LM, Karlinsey D, Turner HL, Rubin V, Furth S, MacPhee K, Duff M, Corey L, Keefer MC, Edupuganti S, Frank I, Maenza J, Baden LR, Hyrien O, Sanders RW, Moore JP, Ward AB, Tomaras GD, Montefiori DC, Rouphael N, and McElrath MJ

Abstract

Stabilized trimers preserving the native-like HIV envelope structure may be key components of a preventive HIV vaccine regimen to induce broadly neutralizing antibodies (bnAbs). We evaluated trimeric BG505 SOSIP.664 gp140, formulated with a novel TLR7/8 signaling adjuvant, 3M-052-AF/Alum, for safety, adjuvant dose-finding and immunogenicity in a first-in-healthy adult (n=17), randomized, placebo-controlled trial (HVTN 137A). The vaccine regimen appeared safe. Robust, trimer-specific antibody, B-cell and CD4+ T-cell responses emerged post-vaccination. Five vaccinees developed serum autologous tier-2 nAbs (ID50 titer, 1:28-1:8647) after 2-3 doses targeting C3/V5 and/or V1/V2/V3 Env regions by electron microscopy and mutated pseudovirus-based neutralization analyses. Trimer-specific, B-cell-derived monoclonal antibody activities confirmed these results and showed weak heterologous neutralization in the strongest responder. Our findings demonstrate the clinical utility of the 3M-052-AF/alum adjuvant and support further improvements of trimer-based Env immunogens to focus responses on multiple broad nAb epitopes., Key Takeaway/take-Home Messages: HIV BG505 SOSIP.664 trimer with novel 3M-052-AF/alum adjuvant in humans appears safe and induces serum neutralizing antibodies to matched clade A, tier 2 virus, that map to diverse Env epitopes with relatively high titers. The novel adjuvant may be an important mediator of vaccine response.

Published
2024
Full Text
View/download PDF

14. Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.

Author

deCamp AC, Corcoran MM, Fulp WJ, Willis JR, Cottrell CA, Bader DLV, Kalyuzhniy O, Leggat DJ, Cohen KW, Hyrien O, Menis S, Finak G, Ballweber-Fleming L, Srikanth A, Plyler JR, Rahaman F, Lombardo A, Philiponis V, Whaley RE, Seese A, Brand J, Ruppel AM, Hoyland W, Mahoney CR, Cagigi A, Taylor A, Brown DM, Ambrozak DR, Sincomb T, Mullen TM, Maenza J, Kolokythas O, Khati N, Bethony J, Roederer M, Diemert D, Koup RA, Laufer DS, McElrath JM, McDermott AB, Hedestam GBK, and Schief WR

Abstract

Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8 60mer germline-targeting immunogen, higher frequencies of vaccine-induced VRC01-class bnAb-precursor B cells were observed in the high dose compared to the low dose group. Through immunoglobulin heavy chain variable (IGHV) genotyping, statistical modeling, quantification of IGHV1-2 allele usage and B cell frequencies in the naive repertoire for each trial participant, and antibody affinity analyses, we found that the difference between dose groups in VRC01-class response frequency was best explained by IGHV1-2 genotype rather than dose and was most likely due to differences in IGHV1-2 B cell frequencies for different genotypes. The results demonstrate the need to define population-level immunoglobulin allelic variations when designing germline-targeting immunogens and evaluating them in clinical trials., One-Sentence Summary: Human genetic variation can modulate the strength of vaccine-induced broadly neutralizing antibody precursor B cell responses.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results